AstraZeneca oral arthritis drug worse than Humira

[Anonymous]

Good news for Humira

Oral fostamatinib worse than Abbott injectable in Phase IIb

Definitive Phase III results with fostamatinib due in 2013
AstraZeneca shares fall 1.8 percent

 

[Anonymous]

Wow! This is a Syk kinase inhibitor (R788) from Rigel not a good news for Rigel either....

 

[Anonymous]

Wow! This is a Syk kinase inhibitor (R788) from Rigel not a good news for Rigel either....

But good news for Abbott.

 

[Anonymous]

But good news for Abbott.

It's even better news for Pfizer's Jak inhibitor.

 

[Anonymous]

It's even better news for Pfizer's Jak inhibitor.

Lets all go to work for Pfizer.

 

[Anonymous]

But good news for Abbott.

Which is why, of course, the stock is off 69 cents today, and why Wall Street Journal gave it the title of Laggard of The Day in Pharma....

 

[Anonymous]

nope